Enanta Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
03 Enero 2024 - 6:00AM
Business Wire
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage
biotechnology company dedicated to creating small molecule drugs
with an emphasis on treatments for viral infections, today
announced that Jay R. Luly, Ph.D., President and Chief Executive
Officer, will present at the 42nd Annual J.P. Morgan Healthcare
Conference on Wednesday, January 10, 2024 at 9:45 a.m. PT in San
Francisco, CA.
A live webcast of the event will be accessible by visiting the
“Events and Presentations” section on the “Investors” page of
Enanta’s website at www.enanta.com. A replay of the webcast will be
available following the presentation and will be archived for at
least 30 days.
About Enanta Pharmaceuticals, Inc.
Enanta is using its robust, chemistry-driven approach and drug
discovery capabilities to become a leader in the discovery and
development of small molecule drugs with an emphasis on treatments
for viral infections. Enanta’s research and development programs
include clinical candidates for the following disease targets:
respiratory syncytial virus (RSV), SARS-CoV-2 (COVID-19) and
hepatitis B virus (HBV).
Glecaprevir, a protease inhibitor discovered by Enanta, is part
of one of the leading treatment regimens for curing chronic
hepatitis c virus (HCV) infection and is sold by AbbVie in numerous
countries under the tradenames MAVYRET® (U.S.) and MAVIRET®
(ex-U.S.) (glecaprevir/pibrentasvir). A portion of Enanta’s
royalties from HCV products developed under its collaboration with
AbbVie contribute ongoing funding to Enanta’s operations. Please
visit www.enanta.com for more information.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240103111932/en/
Media and Investors Jennifer Viera 617-744-3848
jviera@enanta.com
Enanta Pharmaceuticals (NASDAQ:ENTA)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Enanta Pharmaceuticals (NASDAQ:ENTA)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024